Skip to main content
Search
Search
Search
Search
Main navigation
About pCPA
Who We Are
Governance
Strategic Plan
Reports
What's New at the pCPA
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
pCPA Temporary Access Process (pTAP)
Contact Us
EN
FR
Rybelsus (semaglutide)
pCPA File Number:
22526
Negotiation Status:
Active Negotiation
Indication(s):
Diabetes Mellitus, Type 2
Sponsor/Manufacturer:
Novo Nordisk Canada Inc.
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
2023-11-07
Negotiation Process Concluded:
Not Applicable